Verve Therapeutics Inc (VERV)
5.79
-0.64
(-9.95%)
USD |
NASDAQ |
Nov 13, 16:00
5.81
+0.02
(+0.35%)
After-Hours: 20:00
Verve Therapeutics Revenue (TTM): 24.40M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 24.40M |
| June 30, 2024 | 20.65M |
| March 31, 2024 | 16.05M |
| Date | Value |
|---|---|
| December 31, 2023 | 11.76M |
| September 30, 2023 | 7.626M |
| June 30, 2023 | 5.438M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
5.438M
Minimum
Jun 2023
24.40M
Maximum
Sep 2024
14.32M
Average
13.90M
Median
Revenue (TTM) Benchmarks
| Ardelyx Inc | 251.85M |
| Biomarin Pharmaceutical Inc | 2.753B |
| Sage Therapeutics Inc | 106.40M |
| ALX Oncology Holdings Inc | -- |
| Immuneering Corp | -- |